The U.S. Food and Drug Administration has declined to approve Achieve Life Sciences' application for cytisinicline, a non-nicotine prescription medication intended to help adults quit smoking. In a complete response letter, the agency identified unresolved matters at a third-party manufacturing facility and noted that final product labeling had not been completed by the FDA's action date.
Achieve said the FDA's correspondence did not raise concerns about the drug's clinical safety or efficacy. The company released a statement reiterating that the agency identified manufacturing and labeling issues rather than problems tied to cytisinicline's therapeutic profile.
Cytisinicline is a plant-derived compound designed to reduce nicotine cravings and withdrawal symptoms, including irritability and sleep disturbances, by acting on nicotine receptors in the brain. Unlike nicotine replacement therapies such as patches, gums and lozenges, the medication does not contain or deliver nicotine.
Late-stage clinical trials and extended safety studies involving more than 1,500 participants found that cytisinicline enabled a larger share of adults to stop smoking compared with placebo, with effects that persisted through 24 weeks. Achieve reported no new safety concerns in the longer-term data collected.
The complete response letter follows an anticipated regulatory setback related to an inspection classification assigned to Achieve's former third-party manufacturer. The company previously indicated it expected a CRL after the manufacturer received an FDA inspection classification that required corrective action. Achieve emphasized that the issues cited were general manufacturing matters and not specific to cytisinicline itself.
In response to the FDA's decision, Achieve has relocated its manufacturing to Adare Pharma Solutions, a U.S.-based contract manufacturing organization. The company plans to resubmit its application in the fourth quarter of 2026 and is aiming for potential U.S. approval in the first half of 2027.
Market participants reacted to the regulatory news with intraday volatility. Shares of the company traded higher by more than 10% in early trading following the announcement.
Analysts pointed to the absence of clinical efficacy or safety deficiencies in the FDA letter as a constructive element for the product's regulatory pathway. Brandon Folkes, an analyst at H.C. Wainwright, said that while the complete response letter was expected, the lack of clinical issues supports the notion that cytisinicline remains approvable. Folkes also noted that smoking cessation represents a very large but underdeveloped market, and that cytisinicline could potentially help reactivate it.
Regulatory timing and supply chain changes will determine when cytisinicline might reach patients and prescribers. Achieve's plan to move production to a U.S. manufacturer and to resubmit in late 2026 establishes a clear timeline, but the FDA's next review and any additional agency requests will shape the ultimate approval timetable.